vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and DigitalOcean Holdings, Inc. (DOCN). Click either name above to swap in a different company.

DigitalOcean Holdings, Inc. is the larger business by last-quarter revenue ($242.4M vs $196.0M, roughly 1.2× Axsome Therapeutics, Inc.). DigitalOcean Holdings, Inc. runs the higher net margin — 10.6% vs -14.6%, a 25.2% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 18.3%). DigitalOcean Holdings, Inc. produced more free cash flow last quarter ($31.1M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 14.5%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

DigitalOcean Holdings, Inc. is an American multinational technology company and cloud service provider. The company is headquartered in Broomfield, Colorado, US, with 15 globally distributed data centers. DigitalOcean provides developers, startups, and SMBs with cloud infrastructure-as-a-service platforms.

AXSM vs DOCN — Head-to-Head

Bigger by revenue
DOCN
DOCN
1.2× larger
DOCN
$242.4M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+46.7% gap
AXSM
65.0%
18.3%
DOCN
Higher net margin
DOCN
DOCN
25.2% more per $
DOCN
10.6%
-14.6%
AXSM
More free cash flow
DOCN
DOCN
$49.8M more FCF
DOCN
$31.1M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
14.5%
DOCN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
AXSM
AXSM
DOCN
DOCN
Revenue
$196.0M
$242.4M
Net Profit
$-28.6M
$25.7M
Gross Margin
58.7%
Operating Margin
-13.8%
16.0%
Net Margin
-14.6%
10.6%
Revenue YoY
65.0%
18.3%
Net Profit YoY
61.9%
40.5%
EPS (diluted)
$-0.55
$0.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
DOCN
DOCN
Q4 25
$196.0M
$242.4M
Q3 25
$171.0M
$229.6M
Q2 25
$150.0M
$218.7M
Q1 25
$121.5M
$210.7M
Q4 24
$118.8M
$204.9M
Q3 24
$104.8M
$198.5M
Q2 24
$87.2M
$192.5M
Q1 24
$75.0M
$184.7M
Net Profit
AXSM
AXSM
DOCN
DOCN
Q4 25
$-28.6M
$25.7M
Q3 25
$-47.2M
$158.4M
Q2 25
$-48.0M
$37.0M
Q1 25
$-59.4M
$38.2M
Q4 24
$-74.9M
$18.3M
Q3 24
$-64.6M
$32.9M
Q2 24
$-79.3M
$19.1M
Q1 24
$-68.4M
$14.1M
Gross Margin
AXSM
AXSM
DOCN
DOCN
Q4 25
58.7%
Q3 25
59.6%
Q2 25
59.9%
Q1 25
61.4%
Q4 24
57.1%
Q3 24
60.2%
Q2 24
61.0%
Q1 24
60.7%
Operating Margin
AXSM
AXSM
DOCN
DOCN
Q4 25
-13.8%
16.0%
Q3 25
-27.0%
19.6%
Q2 25
-24.5%
16.3%
Q1 25
-46.9%
17.9%
Q4 24
-61.1%
15.9%
Q3 24
-59.8%
12.4%
Q2 24
-89.5%
11.6%
Q1 24
-89.7%
6.2%
Net Margin
AXSM
AXSM
DOCN
DOCN
Q4 25
-14.6%
10.6%
Q3 25
-27.6%
69.0%
Q2 25
-32.0%
16.9%
Q1 25
-48.9%
18.1%
Q4 24
-63.1%
8.9%
Q3 24
-61.7%
16.6%
Q2 24
-91.0%
9.9%
Q1 24
-91.1%
7.7%
EPS (diluted)
AXSM
AXSM
DOCN
DOCN
Q4 25
$-0.55
$0.23
Q3 25
$-0.94
$1.51
Q2 25
$-0.97
$0.39
Q1 25
$-1.22
$0.39
Q4 24
$-1.54
$0.21
Q3 24
$-1.34
$0.33
Q2 24
$-1.67
$0.20
Q1 24
$-1.44
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
DOCN
DOCN
Cash + ST InvestmentsLiquidity on hand
$322.9M
$254.5M
Total DebtLower is stronger
$1.3B
Stockholders' EquityBook value
$88.3M
$-28.7M
Total Assets
$689.8M
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
DOCN
DOCN
Q4 25
$322.9M
$254.5M
Q3 25
$325.3M
$236.6M
Q2 25
$303.0M
$387.7M
Q1 25
$300.9M
$360.4M
Q4 24
$315.4M
$428.4M
Q3 24
$327.3M
$439.9M
Q2 24
$315.7M
$443.1M
Q1 24
$331.4M
$419.1M
Total Debt
AXSM
AXSM
DOCN
DOCN
Q4 25
$1.3B
Q3 25
$1.3B
Q2 25
Q1 25
Q4 24
$1.5B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
AXSM
AXSM
DOCN
DOCN
Q4 25
$88.3M
$-28.7M
Q3 25
$73.7M
$-69.6M
Q2 25
$73.1M
$-175.2M
Q1 25
$53.2M
$-210.7M
Q4 24
$57.0M
$-203.0M
Q3 24
$92.9M
$-211.7M
Q2 24
$102.9M
$-253.8M
Q1 24
$144.0M
$-286.1M
Total Assets
AXSM
AXSM
DOCN
DOCN
Q4 25
$689.8M
$1.8B
Q3 25
$669.3M
$1.7B
Q2 25
$639.8M
$1.7B
Q1 25
$596.7M
$1.6B
Q4 24
$568.5M
$1.6B
Q3 24
$561.5M
$1.5B
Q2 24
$548.2M
$1.5B
Q1 24
$545.7M
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
DOCN
DOCN
Operating Cash FlowLast quarter
$-18.7M
$57.3M
Free Cash FlowOCF − Capex
$-18.7M
$31.1M
FCF MarginFCF / Revenue
-9.6%
12.8%
Capex IntensityCapex / Revenue
0.0%
10.8%
Cash ConversionOCF / Net Profit
2.23×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$180.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
DOCN
DOCN
Q4 25
$-18.7M
$57.3M
Q3 25
$1.0M
$95.8M
Q2 25
$-32.4M
$92.4M
Q1 25
$-43.4M
$64.1M
Q4 24
$-26.2M
$71.3M
Q3 24
$-18.6M
$73.4M
Q2 24
$-30.1M
$71.3M
Q1 24
$-53.5M
$66.7M
Free Cash Flow
AXSM
AXSM
DOCN
DOCN
Q4 25
$-18.7M
$31.1M
Q3 25
$988.0K
$88.0M
Q2 25
$-32.4M
$59.3M
Q1 25
$-43.7M
$2.1M
Q4 24
$-26.2M
$26.1M
Q3 24
$-18.7M
$16.0M
Q2 24
$-30.2M
$39.5M
Q1 24
$-53.6M
$23.0M
FCF Margin
AXSM
AXSM
DOCN
DOCN
Q4 25
-9.6%
12.8%
Q3 25
0.6%
38.3%
Q2 25
-21.6%
27.1%
Q1 25
-36.0%
1.0%
Q4 24
-22.1%
12.7%
Q3 24
-17.9%
8.1%
Q2 24
-34.6%
20.5%
Q1 24
-71.4%
12.5%
Capex Intensity
AXSM
AXSM
DOCN
DOCN
Q4 25
0.0%
10.8%
Q3 25
0.0%
3.4%
Q2 25
0.0%
15.2%
Q1 25
0.3%
29.4%
Q4 24
0.0%
22.1%
Q3 24
0.1%
28.9%
Q2 24
0.1%
16.6%
Q1 24
0.1%
23.6%
Cash Conversion
AXSM
AXSM
DOCN
DOCN
Q4 25
2.23×
Q3 25
0.60×
Q2 25
2.50×
Q1 25
1.68×
Q4 24
3.91×
Q3 24
2.23×
Q2 24
3.73×
Q1 24
4.72×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

DOCN
DOCN

Scalers$84.3M35%
Scalers Plus$69.9M29%
Builders$64.1M26%
Learners Testers And Other$24.1M10%

Related Comparisons